News

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.
They burst onto the scene four years ago and are taking over the pharmaceutical world. New GLP-1-based drugs like Ozempic, Wegovy or Zepbound are said to be a weight-loss game changer and could drive ...
As weight-loss injections like Mounjaro and Wegovy soar in popularity across the UK, jewellers say they’re seeing an unexpected side effect: wedding and engagement rings no longer fit, and in they are ...
To date, almost 400 reports of acute pancreatitis have been received from people using GLP-1 drugs such as Mounjaro, Wegovy, ...
This follows "hundreds of reports of acute and chronic pancreatitis from people who have taken drugs such as Mounjaro, ...
Spain is investigating Novo Nordisk over concerns it may be illegally advertising its weight loss drugs Ozempic and Wegovy ...
Some less expensive versions of popular weight loss drugs are no longer available to patients, after the Food & Drug ...
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...
These popular medications are now at the center of a major weight loss drug lawsuit. Find out which drugs and involved and ...
These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...